(Q51776428)

English

Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.

scientific article published on 21 October 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

1 reference

based on heuristic

inferred from title

Giuseppe Milone

1

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Massimo Martino

2

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

author name string

Andrea Spadaro

3

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Salvatore Leotta

4

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Annalia Di Marco

5

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Potito Scalzulli

6

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Alessandra Cupri

7

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Valentina Di Martina

8

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Elena Schinocca

9

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Eleonora Spina

10

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Giovanni Tripepi

11

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

language of work or name

0 references

publication date

21 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

164

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

1

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

113-123

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12606

21 January 2018

Identifiers

10.1111/BJH.12606

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24138497

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51776428&oldid=1743738203"